BioCryst Pharmaceuticals
BCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 580
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
95% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $6.52M
73% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 30
34% more capital invested
Capital invested by funds: $1.31B [Q1] → $1.77B (+$453M) [Q2]
33% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 84
10.82% more ownership
Funds ownership: 83.4% [Q1] → 94.22% (+10.82%) [Q2]
7% more funds holding
Funds holding: 272 [Q1] → 292 (+20) [Q2]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Needham
Serge Belanger
|
$17
|
Buy
Maintained
|
4 Aug 2025 |
|
B of A Securities
Tazeen Ahmad
|
$15
|
Buy
Maintained
|
1 Jul 2025 |
|
RBC Capital
Brian Abrahams
|
$13
|
Outperform
Reiterated
|
30 Jun 2025 |
|
Wedbush
Laura Chico
|
$18
|
Outperform
Maintained
|
30 Jun 2025 |
Financial journalist opinion
Based on 3 articles about BCRX published over the past 30 days
